Keywords: Eisai, Halaven, France, Reimbursement, Breast cancer, Xeloda, Failed endpoints

Eisai's Halaven gains French reimbursement; disappointing new research

Article | 11 July 2012

Print This

Japanese drug major Eisai’s (TYO: 4523) Halaven (eribulin), a novel treatment for patients with locally advanced or metastatic breast ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in